advancing stem cell therapies for multiple sclerosis

Since McAllister's 1997 report on a patient with multiple sclerosis (MS) who received a bone marrow transplant for CML, there have been over 600 reports of HSCTs performed primarily for MS. These have been shown to"reduce or eliminate ongoing clinical relapses, halt further progression, and reduce the burden of disability in some patients" that have aggressive highly active multiple sclerosis, "in the absence of chronic treatment with disease-modifying agents".